Cyclolab Ltd strengthens its position in the market
Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.
The Cyclolab Cyclodextrin R&D Laboratory is the world's only all-round cyclodextrin biotech company and has operated as a small R&D company for over 25 years.
Recent changes in the world market and economy revealed the need for a change in the company’s business portfolio, which is why we have decided to share the resources between R&D activity and establishment of manufacturing facilities that enable the production of cyclodextrins in larger scale under GMP circumstances.
To maintain and strengthen our position in the market, CycloLab dedicates special attention to invention and developing patentable technologies, highlighted by the over 130 patents filed by the company so far.
CycloLab committed its operations to serve the pharmaceutical industry by participating in early phase drug development studies (feasibility, formulation optimization, bioequivalence, etc), analysis and GMP manufacturing of various cyclodextrin derivatives to be applied as excipients as well as exploring new applications of CDs such as proteins stabilization, non-viral gene delivery or re-discovery as APIs for several therapeutic areas.
Our goal is to help our partners in the successful development of cyclodextrin-based products via supply of the highest quality cyclodextrins and providing services (analytical, formulation development, custom synthesis or GMP manufacturing). We discover proprietary applications for cyclodextrins and join in collaborations, or out-license these to other companies.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...